Quick Answer
Chemomab Therapeutics Ltd. reported Research And Development Expense of $5.83 million for the year ending 2025.
- Chemomab Therapeutics Ltd. showed a decrease of -48.5% in Research And Development Expense from 2024 to 2025.
- This data is from Chemomab Therapeutics Ltd.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: $4.14 million | Q2 2019: $2.58 million | Q3 2019: $5.57 million | Q1 2020: $1.55 million | Q2 2020: $847.0 thousand | Q3 2020: $1.03 million | Q1 2021: $1.16 million | Q2 2021: $1.31 million | Q3 2021: $1.49 million | Q1 2022: $2.75 million | Q2 2022: $2.91 million | Q3 2022: $5.42 million | Q1 2023: $6.89 million.
- Over the full 8 years of available data (2018 to 2025), Chemomab Therapeutics Ltd.'s Research And Development Expense has declined by 22.4%.
- Historical annual values: Fiscal year 2025: $5.83 million | Fiscal year 2024: $11.33 million | Fiscal year 2023: $18.38 million | Fiscal year 2022: $16.98 million | Fiscal year 2021: $6.33 million | Fiscal year 2020: $4.68 million | Fiscal year 2019: $13.30 million | Fiscal year 2018: $7.51 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: